These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 16097181)

  • 1. [Drug committees are not necessary--therapeutic recommendations are issued anyway].
    Jönsson B
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2085-6: discussion 290-2. PubMed ID: 16097181
    [No Abstract]   [Full Text] [Related]  

  • 2. [Inspra and the drug benefits board: What is the role of the drug committees?].
    Hoffmann M; Dahlqvist R; Levin LA; Silfverhielm B; Skoglund I; Vinge E
    Lakartidningen; 2005 Jul 11-24; 102(28-29):2088, 2090; discussion 290-2. PubMed ID: 16097183
    [No Abstract]   [Full Text] [Related]  

  • 3. [LFN's evaluation of Inspra illustrates the need of drug committees!].
    Malmström R; Hjemdahl P
    Lakartidningen; 2005 May 30-Jun 5; 102(22):1751-2. PubMed ID: 15987055
    [No Abstract]   [Full Text] [Related]  

  • 4. [Health economic evaluation of recommended drug treatment].
    Jendteg S; Persson U; Anell A
    Lakartidningen; 2002 Jul; 99(30-31):3130-1. PubMed ID: 12198934
    [No Abstract]   [Full Text] [Related]  

  • 5. [Drug committees should be abolished because the reality has changed].
    Jönsson B; Arvidsson G; Levin LA; Rehnberg C
    Lakartidningen; 2005 Mar 14-20; 102(11):880-1; discussion 882-3. PubMed ID: 15835525
    [No Abstract]   [Full Text] [Related]  

  • 6. [Medical experts groups and choice of medications. A fair prioritization process guarantees the reliability of the choice of medications].
    Garpenby P
    Lakartidningen; 2004 Aug; 101(32-33):2480-2, 2484. PubMed ID: 15346621
    [No Abstract]   [Full Text] [Related]  

  • 7. [Drug committees, choice of drugs and drug information].
    Lundh B
    Lakartidningen; 1988 Nov; 85(44):3641-3. PubMed ID: 3199994
    [No Abstract]   [Full Text] [Related]  

  • 8. [Health economics evaluations are of great significance for Pharmaceutical Benefit Board's decisions].
    Persson U; Ramsberg J
    Lakartidningen; 2007 Oct 17-23; 104(42):3046-50. PubMed ID: 17985712
    [No Abstract]   [Full Text] [Related]  

  • 9. Guidelines for therapeutic interchange-2004.
    Gray T; Bertch K; Galt K; Gonyeau M; Karpiuk E; Oyen L; Sudekum MJ; Vermeulen LC;
    Pharmacotherapy; 2005 Nov; 25(11):1666-80. PubMed ID: 16232030
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug committees' information leaflets are needed].
    Asberg KH
    Lakartidningen; 2009 Sep 16-22; 106(38):2384. PubMed ID: 19848349
    [No Abstract]   [Full Text] [Related]  

  • 11. [What do the Swedish Drug and Therapeutics Committees think about cost savings?].
    Furängen A; Anders C
    Lakartidningen; 2010 Jul 21-Aug 10; 107(29-31):1790; author reply 1790. PubMed ID: 20812570
    [No Abstract]   [Full Text] [Related]  

  • 12. [Choice of drugs--by whom, for whom and to what costs?].
    Frisk M; Strömstedt A
    Lakartidningen; 2000 Sep; 97(39):4343-6. PubMed ID: 11076479
    [No Abstract]   [Full Text] [Related]  

  • 13. [Drug committees in Denmark. Status and future challenges].
    Rabøl R; Kampmann JP; Christensen HR
    Ugeskr Laeger; 2004 Aug; 166(35):2988-91. PubMed ID: 15387009
    [No Abstract]   [Full Text] [Related]  

  • 14. [The drug committees will play a key role].
    Gennser M
    Lakartidningen; 1993 Nov; 90(46):4078, 4083. PubMed ID: 8259004
    [No Abstract]   [Full Text] [Related]  

  • 15. [Drug committees welcome the SBU hypertension report. A number of patients can be offered cost-effective, evidence-based therapy].
    Ohlsson O
    Lakartidningen; 2004 Dec; 101(49):3984-5. PubMed ID: 15633336
    [No Abstract]   [Full Text] [Related]  

  • 16. [Lists presented by eight drug committees compared. The number of preparations varies. Similar views on the most expensive drugs].
    Bergman U; Myrhed M
    Lakartidningen; 1996 Apr; 93(15):1459-60. PubMed ID: 8667738
    [No Abstract]   [Full Text] [Related]  

  • 17. [Future drug committees--institutions for cooperation and information].
    Odeberg H; Lenhoff K
    Lakartidningen; 1989 Jan; 86(1-2):34. PubMed ID: 2911227
    [No Abstract]   [Full Text] [Related]  

  • 18. [Priorities by the board of drug benefits--guidelines clarify. Clinical trials are not sufficient for decisions on subsidizing].
    Carlsson P
    Lakartidningen; 2003 Jul; 100(30-31):2428-9. PubMed ID: 12914137
    [No Abstract]   [Full Text] [Related]  

  • 19. [Local drug information--who is responsible?].
    Henningsson S
    Lakartidningen; 1994 Apr; 91(15):1485-6. PubMed ID: 8183031
    [No Abstract]   [Full Text] [Related]  

  • 20. Do P&T committees have enough power? Plans and PBMs are divided about sharing drug prices with clinicians. Is it better to have an administrative committee determine the formulary?
    Cross M
    Manag Care; 2007 Apr; 16(4):39-42. PubMed ID: 17491288
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.